IMMX
$11.43+0.65 (+6.08%)
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead prod...
Recent News
Breakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX)
We feel now is a pretty good time to analyse Immix Biopharma, Inc.'s ( NASDAQ:IMMX ) business as it appears the company...
We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Immix...
Immix Biopharma, Inc. (NASDAQ:IMMX) surges 10%; individual investors who own 56% shares profited along with insiders
Key Insights Immix Biopharma's significant individual investors ownership suggests that the key decisions are...
Discover Immix Biopharma And 2 Other Promising Penny Stocks
As the U.S. stock market experiences a rise, buoyed by recent labor market data and anticipation of the August jobs report, investors are keenly observing potential shifts in monetary policy. Amidst this backdrop, penny stocks continue to intrigue those looking for opportunities beyond the mainstream indices. Although often associated with smaller or newer companies, these stocks can offer significant growth potential when supported by strong financials and robust fundamentals. In this...
Immix Biopharma Loses US$9.2m Market Value But Insiders See Windfall Of US$19k
Insiders who bought Immix Biopharma, Inc. ( NASDAQ:IMMX ) in the last 12 months may probably not pay attention to the...